For victims of breast cancer, the leading cause of cancer death among women worldwide, Comprehensive Blood and Cancer Center is offering a new hope. Following a four year clinical trial at CBCC, Pablociclib, a breakthrough pharmaceutical by Pfizer, is providing that hope.
Pablociclib works by specifically targeting the CDK 4 and CDK 6 kinases. By suppressing the CDK 4 and CDK 6 kinases, two closely related enzymes that enable tumor cell progression, tumor cells are prevented from developing during the S-phase of the cell cycle, the cycle in which DNA replication occurs.
According to CBCC director Ravi Patel, MD, Pablociclib has shown a “significant improvement in what is called survival.” CBCC’s four year trial, which tested eleven patients, has proven a success. One of the patients, at age 78, is “happy, healthy and, once again, regularly playing golf.”
Pablociclib has received the Federal Food and Drug…
View original post 106 more words